How much revenue does Dizal (Jiangsu) Pharmaceutical make?

Dizal (Jiangsu) Pharmaceutical reported 359.90 million CNY in revenue for fiscal year 2024, up 294.2% from 91.29 million CNY in fiscal year 2023. In Q2 2025 revenue was 195.36 million CNY.

What companies are similar to Dizal (Jiangsu) Pharmaceutical?

Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Sichuan Biokin Pharmaceutical Co.,Ltd. (688506.SS), Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SS), Junshi BIO (688180.SS), Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266.SS).

Dizal (Jiangsu) Pharmaceutical Co., Ltd. (688192.SS) Stock

About Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Dizal (Jiangsu) Pharmaceutical Co., Ltd., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of oncology and hematologic disorders. Its assets include the ZEGFROVY, for the treatment of solid tumors; Gao Ruizhe to treat hematological malignancy, solid tumors, and immunological diseases; Birelentinib indicated for hematological malig...

At a glance

Dizal (Jiangsu) Pharmaceutical reported revenue of 359.90 million CNY for fiscal year 2024, up 294.2% from fiscal year 2023, and net income of -845.96 million CNY. In Q2 2025 (the quarter ended June 30, 2025) revenue was 195.36 million CNY, up 59.8% from a year before.

Figures from company filings; latest fiscal year ended December 31, 2024.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.